RELEVIUM
About RELEVIUM
Pancreatic cancer has the lowest survival rate among other cancers and is responsible for 95,000 deaths every year in the EU. We at RELEVIUM aim to tackle this issue and improve the quality of life for advanced pancreatic cancer patients. This is done by reducing pain and cachexia through highly personalized nutrition, physical activity, and pain management strategies (in addition to chemotherapy). By doing so, RELEVIUM will empower patients and assist them in living a less strenuous life while they are forced to endure this difficult time.
Through our wearable technology solutions, indicators of the patient's health will be gathered and transformed through the AI-driven health services, and thus aggregated to a dashboard in which the information will be available to the patients and clinicians. With these continuous remote monitoring technologies, the multimodal supportive intervention will be able to observe pain estimation, estimation of muscle mass, nutrition levels, and physical activity levels.
​
Our Mission Is to Empower
Improving overall palliative care for the lives of patients with pancreatic cancer is the primary goal of RELEVIUM. QoL will be improved, the pain will be effectively managed, sarcopenia will be reduced, ECOG status will be improved, and maintaining levels of treatment accessibility are all feasible with the team's combined efforts, the technology, and the innovation that exists within RELEVIUM.
4.6
Months life expectancy at time of diagnosis
100,000
New cases of pancreatic cancer every year in Europe
40 years
The only cancer that has not seen improvement in survival in 40 years